Clinical trials: Drug Eluting Stent
Coronary Artery Disease
Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)
The purpose of this study is to compare the safety and effectiveness of drug-eluting stent implantation compared to optimal medical treatment in patients with chronic total occlusion.
- Trial name
- NCT01078051
- Testing
- Cypher, xience, Endeavor, Taxus, optimal medical therapy
- Where
- 26 sites in India, Indonesia and 3 more
- Volunteers
- 840 people
- Sponsor
- Seung-Jung Park
In-Stent Restenosis
P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses
The aim of the study is to assess the safety and efficacy of the Paclitaxel-eluting PTCA-balloon in the treatment of in-stent restenoses in native coronary arteries with reference diameters between 2.5 mm and 3.5 mm and ≤ 22 mm…
- Trial name
- NCT00393315
- Testing
- paclitaxel coated balloon catheter
- Where
- 10 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital, Saarland
Coronary Artery Diseases
BIOTRONIK - BIOFLOW-III Registry French Satellite
For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success.
- Trial name
- NCT02273648
- Testing
- Drug Eluting Stent (DES)
- Where
- 50 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Biotronik France
In Stent Restenosis
DEB vs Thin-DES in DES-ISR: Long Term Outcomes (DEB Dragon Registry)
Data regarding the usefulness of percutaneous coronary intervention (PCI) with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR) in every day clinical practice is…
- Trial name
- DEB-DRAGON (NCT04415216)
- Testing
- percutaneous coronary intervention
- Where
- 9 sites in Poland
- Volunteers
- 1,369 people
- Sponsor
- Medical University of Silesia
Acute ST-elevation Myocardial Infarction
the Effect of Prolonged Inflation Time During Stents Deployment for ST-elevation Myocardial Infarction
The purpose of this study is to determine whether prolonged inflation time on drug-eluting stents deployment for ST-elevation myocardial Infarction was better than conventional stents deployment.
- Trial name
- NCT03199014
- Testing
- deploying the Drug-eluting Stents with a prolonged time, deploying the Drug-eluting Stents with a conventional time
- Where
- China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Coronary Artery Disease, Antiplatelet Drugs
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and…
- Trial name
- OPTION2 (NCT06451198)
- Testing
- Indobufen, Aspirin, Ticagrelor
- Where
- China
- Volunteers
- 2,846 people
- Sponsor
- Shanghai Zhongshan Hospital
Coronary Artery Disease, Diabetes Mellitus
Assessment of Surface Coverage of Two Types of Drug-eluting Stent in Diabetes Mellitus and Non-Diabetes Mellitus
Diabetic patients are prone to a diffuse and rapidly progressive form of atherosclerosis. Both clinical and angiographic outcomes following percutaneous coronary intervention (PCI) are poor in patients with DM compared with those…
- Trial name
- NCT01023919
- Testing
- Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Harbin Medical University
Coronary Artery Disease, Chronic Coronary Syndrome
Very Long Versus Overlapping Stents in Long Coronary Lesions
This study is performed to compare the angiographic and clinical outcomes of the use of single long stent versus overlapping stents in the treatment of long coronary lesions in patients with chronic coronary syndrome.
- Conditions
- Coronary Artery Disease, Chronic Coronary Syndrome, Drug Eluting Stents
- Trial name
- NCT04738344
- Testing
- Percutaneous Coronary Intervention and Stent Implantation
- Where
- 2 sites in Egypt
- Sponsor
- The Young Investigator Group of Cardiovascular Research
Cardiovascular Complications, Hemorrhagic Complications
Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery
Non cardiac surgery in patients with coronary stents is complicated with cardiovascular and hemorrhagic events associated with perioperative management of antiplatelet agents.
- Trial name
- RECO (NCT01045850)
- Where
- 53 sites in France
- Volunteers
- 1,312 people
- Sponsor
- University Hospital, Grenoble
Coronary Heart Disease
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study
The goal of the PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study is to evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected…
- Trial name
- PE-Prove (NCT01148329)
- Testing
- Coronary stenting
- Where
- 40 sites in Austria, Belgium and 9 more
- Volunteers
- 1,010 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Stenosis
Angiography Study of BioNIR Drug Eluting Stent System (NIREUS)
The NIREUS study aims to demonstrate angiographic non-inferiority for the BioNIR Ridaforolimus Eluting Coronary Stent System (hereafter referred to as BioNIR) in comparison to the Resolute zotarolimus-eluting stent (hereafter…
- Trial name
- NIREUS (NCT01995500)
- Testing
- BioNIR, Resolute
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Medinol Ltd.
Coronary Artery Disease, Restenoses, Coronary
Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
The hypothesis of the study is, that there is a significant interaction in treatment effect between the OCT pattern of neointima (heterogeneous or homogeneous) and the type of percutaneous coronary intervention (drug-eluting…
- Trial name
- ISAR-DESIRE5 (NCT05544864)
- Testing
- Drug eluting stent (DES), Drug coated ballloon (DCB)
- Where
- 5 sites in Germany, Spain
- Volunteers
- 376 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)
The objective of this study is to evaluate effectiveness and safety of drug-eluting stent implantation in the "real world" daily practice.
- Trial name
- NCT01788592
- Where
- South Korea
- Volunteers
- 50,000 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease, Stent Thrombosis
Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
To compare treatment with aspirin alone versus the combined antiplatelet treatment aspirin and clopidogrel after 12 months of combined antiplatelet treatment following drug-eluting stent (DES) implantation.
- Conditions
- Coronary Artery Disease, Stent Thrombosis, Myocardial Ischemia
- Trial name
- OPTIDUAL (NCT00822536)
- Testing
- Aspirin and Clopidogrel, Aspirin
- Where
- France
- Volunteers
- 1,798 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Artery Disease, Myocardial Ischemia
AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population
Prospective, Randomized (2:1), active control, single-blind, non-inferiority, multicenter, Japanese Clinical Trial to evaluate the safety and effectiveness of Absorb™ BVS (AVJ-301) in the treatment of subjects with ischemic heart…
- Trial name
- ABSORB JAPAN (NCT01844284)
- Testing
- XIENCE PRIME®/XIENCE Xpedition™, Absorb™ BVS
- Where
- 39 sites in Japan
- Volunteers
- 400 people
- Sponsor
- Abbott Medical Devices
Cardiovascular Diseases, Coronary Artery Disease
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease
The registry aims to evaluate the safety, performance and efficacy of the Everolimus-eluting bioresorbable vascular scaffold (BVS) system in patients with de novo native coronary artery lesions in all-day clinical practice.
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease, Myocardial Ischemia, Coronary Disease
- Trial name
- ASSURE (NCT01583608)
- Where
- 6 sites in Germany
- Volunteers
- 183 people
- Sponsor
- Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.
Coronary Artery Disease, Dyslipidemias
Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)
the investigators would like to compare the differences between roschvastin and atovastatin in patients who require high-dose statin/ejetimib to undergo a new generation of drug elution stent implantation for cardiovascular…
- Trial name
- NCT05910476
- Testing
- a high dose of statin/ezetimib
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Coronary Artery Disease
Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting
The purpose of this study is to determine whether a 6 month duration of clopidogrel therapy after DES implantation is not inferior to that of a 12 month therapy.
- Trial name
- ISAR-SAFE (NCT00661206)
- Testing
- Clopidogrel
- Where
- 40 sites in United States, Albania and 11 more
- Volunteers
- 4,005 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Atherosclerosis of Native Arteries of the Extremities
Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
To determine whether the Boston Scientific nitinol drug-eluting stent shows acceptable performance at 9 months when treating Superficial Femoral (SFA) and/or Proximal Popliteal Artery (PPA) lesions.
- Trial name
- MAJESTIC (NCT01820637)
- Testing
- The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
- Where
- 13 sites in Australia, Austria and 3 more
- Volunteers
- 57 people
- Sponsor
- Boston Scientific Corporation
Peripheral Vascular Disease
The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions
The objective of this clinical investigation is to evaluate the early and mid-term outcome (after 6 and 12 months) and the long-term (up to 24 months) outcome of the Zilver PTX paclitaxel-eluting stent (Cook) versus bypass…
- Trial name
- ZILVERPASS (NCT01952457)
- Testing
- Zilver PTX, prosthetic bypass
- Where
- 5 sites in Belgium
- Volunteers
- 220 people
- Sponsor
- Flanders Medical Research Program